Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REACT

Financiado

Reprogramming of Tumor Stroma to Enhance Cancer Immunotherapy

Cancer immunotherapies have shown impressive success in cancer treatment. However, these therapies are limited to certain type of cancers, and success rate is still low. In particular, certain types of solid tumors containing an a... ver más

30/11/2025

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

INSTITUT PASTEUR No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-12

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CAR-TIME Drivers and Brakes of CAR T Cell Efficacy Determined by the... 1M€ Cerrado

STIC-GBM Spatio-temporal dynamics of immune circuitry in glioblastoma... 174K€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

CANCER-DC Dissecting Regulatory Networks That Mediate Dendritic Cell S... 2M€ Cerrado

LiveBioThx Live biotherapeutics to potentiate cancer immunotherapy 150K€ Cerrado

EXPAND IT EXPANDing Immune Cells and their Tumor Antigens during check... 3M€ Cerrado

Duración del proyecto: 20 meses Fecha Inicio: 2024-03-12
Fecha Fin: 2025-11-30

Líder del proyecto

INSTITUT PASTEUR No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Cancer immunotherapies have shown impressive success in cancer treatment. However, these therapies are limited to certain type of cancers, and success rate is still low. In particular, certain types of solid tumors containing an abundant stroma, which represent a majority of epithelial derived cancer, respond very poorly to immunotherapies. In these tumors, a major challenge for the development of novel cancer immunotherapies is represented by the tumor microenvironment (TME), a highly hypoxic and immunosuppressive environment which prevents proper tumor infiltration and functioning of effector immune cells. Recent discoveries identified tumor-activated mesenchymal stromal cells (MSCs) developing within the TME, and showed that they represent a major brake for efficient antitumor immunity in solid tumors. In this project, we will investigate the potential of a novel approach and therapeutic avenue to target specific populations of MSCs within the TME, and determine the synergistic effect with immunotherapies to improve treatment efficacy in solid tumors. In the long term, this project aims at overcoming a major barrier in utilizing cancer immunotherapies in solid tumors.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores